Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies

American Journal of Transplantation

Volumn 10, Issue 5, 2010, Pages 1254-1262

  Bachler K ^a   Amico, P ^a   Honger G ^a   Bielmann, D ^a   Hopfer, H ^b   Mihatsch, M J ^b   Steiger, J ^a   Schaub, S ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Antibody mediated rejection; ATG; HLA antibodies; Intravenous immunoglobulins

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLOGRAFT; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HLA MATCHING; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOREGULATION; INCIDENCE; KIDNEY GRAFT REJECTION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETRANSPLANTATION;

ANTIBODIES; CLINICAL PROTOCOLS; FEMALE; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; RISK FACTORS; T-LYMPHOCYTES; TISSUE DONORS;

EID: 77951245486     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03093.x     Document Type: Article

References (39)

1. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006 6 : 346 351. (Pubitemid 43382170)
2. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003 3 : 1488 1500. (Pubitemid 37541506)
3. Thielke JJ, West-Thielke PM, Herren HL et al. Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience. Transplantation 2009 87 : 268 273.
4. Akalin E, Dinavahi R, Friedlander R et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008 3 : 1160 1167.
5. Mai ML, Ahsan N, Wadei HM et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009 87 : 227 232.
6. Lefaucheur C, Suberbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008 8 : 324 331.
7. Haririan A, Nogueira J, Kukuruga D et al. Positive cross-match living donor kidney transplantation: Longer-term outcomes. Am J Transplant 2009 9 : 536 542.
8. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009 87 : 1681 1688.
9. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: Are they relevant? Transplantation 2008 85 : 1200 1204. (Pubitemid 351590199)
10. Bielmann D, Honger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007 7 : 626 632. (Pubitemid 46376450)
11. Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement degradation product C4d in renal allografts: Diagnostic and therapeutic implications. J Am Soc Nephrol 2002 13 : 242 251. (Pubitemid 34042034)
12. Seemayer CA, Gaspert A, Nickeleit V, Mihatsch MJ. C4d staining of renal allograft biopsies: A comparative analysis of different staining techniques. Nephrol Dial Transplant 2007 22 : 568 576. (Pubitemid 46189903)
13. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008 8 : 753 760. (Pubitemid 351347767)
14. Klitz W, Maiers M, Spellman S et al. New HLA haplotype frequency reference standards: High-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans. Tissue Antigens 2003 62 : 296 307. (Pubitemid 37204584)
15. Mueller NJ, Weisser M, Fehr T et al. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. Transpl Infect Dis 2009. Epub ahead of print. doi
16. Haas M, Montgomery RA, Segev DL et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007 7 : 576 585. (Pubitemid 46376440)
17. Loupy A, Suberbielle-Boissel C, Hill GS et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009 9 : 2561 2570.
18. El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009 9 : 527 535.
19. Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009 9 : 201 209.
20. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008 86 : 1754 1761.
21. Trivedi HL, Terasaki PI, Feroz A et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009 87 : 1555 1561.
22. Vlad G, Ho EK, Vasilescu ER et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009 70 : 589 594.
23. Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009 70 : 584 588.
24. Aubert V, Venetz JP, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009 70 : 580 583.
25. Van Den Berg-Loonen EM, Billen EV, Voorter CE et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008 85 : 1086 1090.
26. Amico P, Honger G, Steiger J, Schaub S. Utility of the virtual crossmatch in solid organ transplantation. Curr Opin Organ Transplant 2009 14 : 656 661.
27. Burns JM, Cornell LD, Perry DK et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008 8 : 2684 2694.
28. Reinsmoen NL, Lai CH, Vo A et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008 86 : 820 825.
29. Kushihata F, Watanabe J, Mulder A, Claas F, Scornik JC. Human leukocyte antigen antibodies and human complement activation: Role of IgG subclass, specificity, and cytotoxic potential. Transplantation 2004 78 : 995 1001. (Pubitemid 39391860)
30. Tan CD, Sokos GG, Pidwell DJ et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant 2009 9 : 2075 2084.
31. Salama AD, Delikouras A, Pusey CD et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloantibody. Am J Transplant 2001 1 : 260 269. (Pubitemid 33674170)
32. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009 9 : 2312 2323.
33. Park WD, Grande JP, Ninova D et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003 3 : 952 960. (Pubitemid 36917540)
34. Haas M. The significance of C4d staining with minimal histologic abnormalities. Curr Opin Organ Transplant 2010 15 : 21 27.
35. Tambur AR, Ramon DS, Kaufman DB et al. Perception versus reality?: Virtual crossmatch-how to overcome some of the technical and logistic limitations. Am J Transplant 2009 9 : 1886 1893.
36. Vaidya S, Partlow D, Susskind B, Noor M, Barnes T, Gugliuzza K. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation 2006 82 : 1524 1528. (Pubitemid 44967637)
37. Nikaein A, Cherikh W, Nelson K et al. Organ procurement and transplantation network/united network for organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients. Transplantation 2009 87 : 557 562.
38. Cai J, Terasaki PI, Anderson N, Lachmann N, Schonemann C. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009 88 : 226 230.
39. El-Awar N, Terasaki PI, Nguyen A et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009 70 : 844 853.